Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Patent
1997-09-26
2000-05-16
Hauda, Karen M.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
424 91, 4242771, 424 931, 800 3, 800 8, 800 18, 800 14, C12N 500, A61K 4900
Patent
active
06063359&
ABSTRACT:
A method for screening substances for oncogenic activity is disclosed. The method involves administering the substance to an animal lacking responsiveness to interferon.gamma. and detecting a higher frequency or earlier time of tumor formation in the test animal compared to control animals. In addition, a method is provided for predicting the aggressiveness of a tumor in a patient.
REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 5087571 (1992-02-01), Leder et al.
patent: 5174986 (1992-12-01), Berns
patent: 5510099 (1996-04-01), Short et al.
patent: 5602300 (1997-02-01), Gossen et al.
Venditti, J.M. (1981) In: Design of Models for Testing Cancer Therapeutic Agents, ed. I. Fidler and R.J. White, pp. 80-94. Van Nostrand Reinhold, New York.
Salomon, J. C. (1980) Cancer Induction by Methylcholanthrene and Metastatic Spread of Transplantable Tumor in Chediak Higashi (Beige) Mice. Cancer Immunol. Immunother., vol. 8(1): 67-70.
Gaspari et al., Impaired Interferon Production and Natural Killer Cell Activation in Patients with the Skin Cancer-prone Disorder, Xeroderma Pigmentosum, J. of Clinical Invest. 92:1135-1142 (1993).
Bach et al., The IFN.gamma. Receptor: A Paradigm for Cytokine Receptor Signaling, Annu. Rev. Immunol, 15:563-91 (1997).
Broek et al., Decreased Tumor Surveillance in Perforin-deficient Mice, J. Exp. Med., 184:1781-1790 (1996).
Dighe et al., Enhanced In Vivo Growth and Resistance to Rejection of Tumor Cells Expressing Dominant Negative IFN.gamma. Receptors, Immunity, 1:147-456 (1994).
Dighe et al., Tissue-Specific Targeting of Cytokine Unresponsiveness in Transgenic Mice, Immunity, 3:657-666 (1995).
Donehower et al., Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors, Nature, 356:215-221 (1992).
Farrar et al., Identification of a functionally important sequence in the C terminus of the interferon-.gamma. receptor, Proc. Natl. Acad. Sci., 89:11706-11710 (1992).
Farrar et al., Identification of Two Regions within the Cytoplasmic Domain of the Human Interferon-.gamma. Receptor Required for Function, The Journal of Biological Chemistry, 266:19626-19635 (1991).
Farrar et al., The Molecular Cell Biology of Interferon-.gamma. and its Receptor, Annu. Rev. Immunol, 11:571-611 (1993).
Harvey et al., Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice, nature genetics, 5:225-229 (1993).
Huang et al., Immune Response in Mice That Lack the Interferon-.gamma. Receptor, Science, 259:1742-1745 (1993).
Meraz et al., Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK-STAT Signaling Pathway, Cell, 84:431-442 (1996).
Rogers et al., Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice, Proc. natl. Acad. Sci., 89:1011-1015 (1992).
Storer et al., Short-term carcinogenesis bioassay of genotoxic procarcinogens in PIM transgenic mice, Carcinogenesis, 16:285-293 (1995).
Tennant et al., Identifying Chemical Carcinogens and Assessing Potential Risk in Short-term Bioassays Using Transgenic Mouse Models, Environmental Health Perspectives, 103:942-950 (1995).
Yamamoto et al., Rapid induction of more malignant tumors by various geneotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice, Carcinogenesis, 17:2455-2461 (1996).
Old Lloyd J.
Schreiber Robert
Hauda Karen M.
Washington University
LandOfFree
Method for determining oncogenic activity of a substance does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for determining oncogenic activity of a substance, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for determining oncogenic activity of a substance will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-256181